Marisa Wexler, MS, Senior Science Writer —

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).

An imaging technique called holomedicine helped surgeons in Singapore make sure they removed a part of a liver from a living adult donor that was…

A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…

Treatment with Ocaliva (obeticholic acid) — an oral therapy with conditional approval in both the U.S. and Europe — reduced levels of additional markers…

Children with biliary atresia who have a serious condition called acute-on-chronic liver failure (ACLF) tend to require a longer stay in the hospital and are…

An intermittent fasting regimen reduced liver fat buildup and lowered the likelihood of liver cancer in mouse models of metabolic dysfunction-associated steatohepatitis (MASH), a severe…

Primary biliary cholangitis (PBC), a rare autoimmune liver disease, shares 10 genetic risk factors with inflammatory bowel disease (IBD), a group of inflammatory conditions…

Reduced activity of a protein called GPR75 appears to help prevent the buildup of fat in the liver and the subsequent development of metabolic dysfunction-associated…

Researchers at the University of California San Diego (UCSD) have created a molecule, named antisense oligonucleotide (ASO) 56, that is able to potently reduce liver…

The U.S. government soon will launch a first national study to assess the prevalence of metabolic dysfunction-associated steatotic liver disease, or MASLD — a liver…